Gut microbiota and short-chain fatty acids in idiopathic REM sleep behavior disorder and Parkinson’s disease
- 1Department of Neurology, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University
- 2Department of Neurology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou Normal University
Abstract
Background: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a prodromal stage of Parkinson’s disease (PD). This study aimed to investigate whether gut microbiota and short-chain fatty acids (SCFAs) show consistent alterations in iRBD and PD with RBD patients.
Methods: We enrolled 29 iRBD, 24 PD with RBD, 17 PD without RBD, and 18 normal controls (NC). Fecal microbiota composition was analyzed via 16S rRNA sequencing, and SCFA concentrations via gas chromatography–mass spectrometry (GC–MS). Clinical symptoms were assessed using motor and non-motor scales, and Spearman correlation analysis was performed to explore interrelationships.
Results: Microbiota analysis revealed that, compared with NC, Bifidobacterium , Blautia_A , and Azospira_A were significantly enriched, whereas Agathobaculum , Clostridium_Q , Faecalibaculum , Photobacterium , Copromonas , UBA3402 , Acetobacter , and Sutterella were reduced in both iRBD and PD with RBD groups. SCFA analysis showed significantly decreased fecal butyric acid and propionic acid levels in both groups versus NC. Correlation analysis demonstrated that in the iRBD group, Bifidobacterium positively correlated with RBD disease duration; butyric acid negatively correlated with NMSS and RBD-HK; propionic acid negatively correlated with NMSS, RBD-HK, and SCOPA-AUT. In the PD with RBD group, Bifidobacterium negatively correlated with SCOPA-AUT and positively with HAMD-17; butyric acid positively correlated with MDS-UPDRS III.
Conclusion: iRBD and PD with RBD share similar gut dysbiosis and SCFA abnormalities. Elevated Bifidobacterium and decreased butyric acid and propionic acid are candidate markers for iRBD risk stratification, but correlation does not imply predictive ability. Their value in predicting progression to PD requires validation in longitudinal iRBD cohorts.
Related
- Impaired Dynamic Cerebral Autoregulation Across the REM Sleep Behavior Disorder Spectrum: Evidence From Isolated REM Sleep Without Atonia to Parkinson's Disease With RBD.
- Colonic LRRK2 expression is increased in Crohn's disease but not in Parkinson's disease and idiopathic RBD
- Dysarthria and idiopathic Parkinson's disease: a current overview of the relationship between speech impairment and quality of life
- Impulse control disorder is linked to dyskinesia development through a cortical network in Parkinson’s disease
- Microbiota-regulated TCDCA associates with Parkinson’s disease severity and promotes BBB dysfunction through VSMC TGR5 signaling in mice
BibTeX
@article{sun2026microbiota,
title = {{Gut microbiota and short-chain fatty acids in idiopathic REM sleep behavior disorder and Parkinson’s disease}},
author = {Xianqian Sun and Weidong Ye and Ying Liu and Xiaoyan Sun and Haiyan Tang},
journal = {Frontiers in Neurology},
year = {2026},
month = nov,
doi = {10.3389/fneur.2026.1982942},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1982942/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut microbiota and short-chain fatty acids in idiopathic REM sleep behavior disorder and Parkinson’s disease
AU - Xianqian Sun
AU - Weidong Ye
AU - Ying Liu
AU - Xiaoyan Sun
AU - Haiyan Tang
PY - 2026
DA - 2026/11/03
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1982942
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1982942/full
AB - Background: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a prodromal stage of Parkinson’s disease (PD). This study aimed to investigate whether gut microbiota and short-chain fatty acids (SCFAs) show consistent alterations in iRBD and PD with RBD patients. Methods: We enrolled 29 iRBD, 24 PD with RBD, 17 PD without RBD, and 18 normal controls (NC). Fecal microbiota composition was analyzed via 16S rRNA sequencing, and SCFA concentrations via gas chromatography–mass spectrometry (GC–MS). Clinical symptoms were assessed using motor and non-motor scales, and Spearman correlation analysis was performed to explore interrelationships. Results: Microbiota analysis revealed that, compared with NC, Bifidobacterium , Blautia_A , and Azospira_A were significantly enriched, whereas Agathobaculum , Clostridium_Q , Faecalibaculum , Photobacterium , Copromonas , UBA3402 , Acetobacter , and Sutterella were reduced in both iRBD and PD with RBD groups. SCFA analysis showed significantly decreased fecal butyric acid and propionic acid levels in both groups versus NC. Correlation analysis demonstrated that in the iRBD group, Bifidobacterium positively correlated with RBD disease duration; butyric acid negatively correlated with NMSS and RBD-HK; propionic acid negatively correlated with NMSS, RBD-HK, and SCOPA-AUT. In the PD with RBD group, Bifidobacterium negatively correlated with SCOPA-AUT and positively with HAMD-17; butyric acid positively correlated with MDS-UPDRS III. Conclusion: iRBD and PD with RBD share similar gut dysbiosis and SCFA abnormalities. Elevated Bifidobacterium and decreased butyric acid and propionic acid are candidate markers for iRBD risk stratification, but correlation does not imply predictive ability. Their value in predicting progression to PD requires validation in longitudinal iRBD cohorts.
SN - 1664-2295
ER -